A Study of DB-1311/BNT324 in Advanced/Metastatic Solid Tumors

Trial status:Recruiting
Trial ID:
DB-1311-O-1001
NCT ID:
NCT05914116
EudraCT ID:
N/A
Sponsor:
The sponsor of a clinical trial is the company, institution or individual that takes responsibility for initiating, managing, and/or financing a clinical investigation. BioNTech collaborates with other pharmaceutical companies or institutions (collaborators) to develop certain new medicines. In particular cases BioNTech's collaborators are leading specific clinical trials and are acting as sponsors accordingly.
DualityBio Inc.
Recruiting

Trial Details

This is a dose-escalation and dose-expansion Phase 1/2a trial to evaluate the safety and tolerability of DB-1311/BNT324 in subjects with advanced solid tumors.

Medical Condition
  • Solid Tumors
    • Trial Drug
  • DB-1311
    • Phase
    Phase 1/Phase 2
    Type
    Interventional
    Estimated Enrolment
    610
    Estimated Trial Date
    Aug 2023 - Sep 2026

    Trial Participant Requirements

    Age
    18+ years
    Sex
    Female & Male
    Healthy Volunteers
    No

    Trial Locations

    Location
    Status
    Location
    Research Site 111
    Tucson, Arizona, United States, 85711
    Status
    Recruiting
    Location
    Research Site 125
    Los Angeles, California, United States, 90033
    Status
    Recruiting
    Location
    Research Site 133
    Los Angeles, California, United States, 90067
    Status
    Recruiting
    Location
    Research Site 103
    Los Angeles, California, United States, 90095
    Status
    Recruiting
    Location
    Research Site 128
    Santa Monica, California, United States, 90403
    Status
    Recruiting
    Location
    Research Site 118
    Celebration, Florida, United States, 34747
    Status
    Recruiting